This alliance leverages the companies’ strengths as two of the world’s leading pharmaceutical companies, combining Boehringer Ingelheim’s solid track record of research-driven innovation and Lilly’s innovative research, experience and pioneering history in diabetes.
On-demand webinar: Chronic kidney disease - what GPs can do to prevent progression and premature death
In this webinar, nephrologist Dr Richard Phoon discusses the latest recommendations on diagnosing and managing your patients with CKD.
Clinical audit: Chronic kidney disease (CKD) - preventing progression and premature death in general practice
In this clinical audit, you will review the management of patients with CKD in line with latest Australian guidelines, utilising the 'kidney health check' to identify the condition in at-risk patients as appropriate. You will stage patients' CKD severity in order to guide their management, and develop comprehensive management plans involving lifestyle, diet and pharmacological management strategies.
Live webinar: Chronic kidney disease: What GPs can do to prevent progression and premature death - 1 August 2024
In this webinar, nephrologist Dr Richard Phoon will discuss the latest recommendations on diagnosing and managing your patients with CKD.
Clinical audit: Management of heart failure with reduced ejection fraction
Review your management of patients with HFrEF (heart failure with reduced ejection fraction) in this clinical audit, and update their treatment to be in line with latest recommendations including the "four pillars" approach.
Heart failure in general practice: Putting latest recommendations into practice advanced course
The new 2022 Australian consensus statement on heart failure has brought significant changes to how general practitioners should manage this condition.
In this advanced course you will understand how to classify HF into heart failure with reduced ejection fraction (HFrEF), heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with preserved ejection fraction (HFpEF).
Updated management of HFrEF in general practice
[Expert video | Duration: 11:06] With new Australian consensus recommendations and available therapies for heart failure with reduced ejection fraction (HFrEF), GPs now have further options for optimising management of their HFrEF patients. Listen to Dr Chee Khoo discuss the updated recommendations and its implications for clinical practice, in both current and newly diagnosed patients.
